DLL3: A Potential Drug Target for Various Diseases (G10683)

Target Name: DLL3

NCBI ID: G10683

DLL3

DLL3: A Potential Drug Target for Various Diseases

DLL3 (Delta-like protein 3 (isoform 1)) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. DLL3 is a transmembrane protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. It is characterized by a unique domain structure that includes a N-terminal cytoplasmic domain, a transmembrane domain, and a C-terminal T-spine domain.

The N-terminal cytoplasmic domain of DLL3 is composed of a single amino acid, Glu215, which is involved in the formation of a disulfide bond with the C-terminal T-spine domain. The transmembrane domain of DLL3 is composed of four amino acids, which include Asp216, Asn217, Glu218, and Lys219. The C-terminal T-spine domain of DLL3 is composed of five amino acids, which include Asp220, Asn221, Glu222, Lys223, and Glu224.

Function

DLL3 is involved in various physiological processes in the body, including cell signaling, neurotransmission, and inflammation. DLL3 has been shown to play a role in the regulation of pain perception, neurogenesis, and neuroprotection. DLL3 has also been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

DLL3 has also been shown to be a potential drug target for various diseases. For example, DLL3 has been shown to be involved in the development of neurocancer, including brain and spinal cord tumors. DLL3 has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. DLL3 has also been shown to be involved in the regulation of pain perception, which is a potential drug target for pain management.

DLL3 has also been shown to be involved in the regulation of inflammation, which is a potential drug target for inflammation management. DLL3 has been shown to play a role in the regulation of inflammation in the brain, which is important for the development and progression of neurodegenerative diseases.

DLL3 has also been shown to be involved in the regulation of cell signaling, which is a potential drug target for cancer and neurodegenerative diseases. DLL3 has been shown to play a role in the regulation of signaling pathways that are important for the development and progression of cancer and neurodegenerative diseases.

Conclusion

DLL3 is a protein that has been identified as a potential drug target and biomarker for various diseases. DLL3 is involved in various physiological processes in the body, including cell signaling, neurotransmission, and inflammation. DLL3 has also been shown to play a role in the regulation of pain perception, neurogenesis, and neuroprotection, as well as the development and progression of neurodegenerative diseases. Based on these findings, DLL3 is a promising target for drug development for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: Delta Like Canonical Notch Ligand 3

Functions: Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity)

The "DLL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets